Encouraging new therapy for primary progressive and relapsing forms of MS
09/10/2015
Roche has today released news of a new therapy, Ocrelizumab, which could be the first effective treatment to slow progression of the primary progressive form of the disease. This new therapy is also claimed to be at least as effective as the two leading treatments for relapsing-remitting MS, Tysabri and Lemtrada. To read more, please follow this link the Reuters…